Updated Nov 4, 2026FDA and CMS public dataIndependent · free · not health advice
GxRadar
Drugs/Fluoxetine 20 mg capsule
Mental health

Fluoxetine 20 mg capsule

Public data on fluoxetine from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.

$0.0292
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-4%
change over five years
peak $0.0351 in 2014-02
69
approved generic applications (ANDAs) on record for Fluoxetine Hydrochloride
34 with a product still marketed · first 2001
Not listed
in FDA's current shortage list
no matching FDA shortage entries

NADAC per unit, monthly

FLUOXETINE HCL 20 MG CAPSULE
Show as table
MonthNADAC per unit ($)
2013-110.03433
2014-020.03514
2014-050.03256
2014-080.02979
2014-110.03087
2015-020.03046
2015-050.03018
2015-080.02805
2015-110.02632
2016-020.02734
2016-050.02641
2016-080.02528
2016-110.02905
2017-020.02640
2017-050.02743
2017-080.02643
2017-110.02539
2018-020.02470
2018-050.02426
2018-080.02970
2018-110.03086
2019-020.03309
2019-050.03146
2019-080.03401
2019-110.03365
2020-020.03143
2020-050.02994
2020-080.02963
2020-110.03288
2021-020.03373
2021-050.03245
2021-080.03304
2021-110.03048
2022-020.03350
2022-050.03202
2022-080.03064
2022-110.03482
2023-020.03226
2023-050.03066
2023-080.03107
2023-110.03128
2024-020.03202
2024-050.02967
2024-080.03002
2024-110.03013
2025-020.03043
2025-050.03120
2025-080.03075
2025-110.02915
2026-020.02989
2026-050.02986
2026-080.02894
2026-110.02924

Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.

Recall records mentioning fluoxetine

openFDA enforcement records, by year reported.

20252
20181
20153
20145

11 records since 2012. A record is one product or lot, not one recall event. Combination products that contain fluoxetine are included.

What these numbers mean

NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.

Most recent recall records

Class IICompleted
Fluoxetine tablets
Reason category: cGMP deviations
FDA recall number D-0455-2025
Class IICompleted
Fluoxetine tablets
Reason category: cGMP deviations
FDA recall number D-0456-2025
Class IIITerminated
Fluoxetine tablets usp
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0578-2018
Class IITerminated
Fluoxetine capsules
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0971-2015
Class IITerminated
Fluoxetine capsules
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0970-2015

Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.

Articles that mention fluoxetine

4 GxRadar articles cite or discuss this drug.

PRICE INDEX · 2014 = 100
Price histories · Data story · 6 min

What pharmacies paid for six generic antidepressants, 2013 to 2026

Federal NADAC data for sertraline, escitalopram, citalopram, fluoxetine, trazodone and duloxetine show three very different price paths since 2013, and FDA approval records help explain them.

Labels & identifiers · Explainer · 6 min

Boxed warnings, FDA's most prominent label warning, explained

What 21 CFR 201.57 requires of a boxed warning, how many prescription labels carry one (about a third, by two counts 14 years apart), and why a generic's box matches the brand's.

The approval pathway · Explainer · 5 min

Pediatric exclusivity and the six months it adds before generics

A brand company that studies its drug in children at FDA's written request can win six more months of protection from generics. How the 1997 incentive works, what it attaches to, and what FDA's own lists show.

Labels & identifiers · Explainer · 5 min

Medication Guides and patient package inserts

What 21 CFR Part 208 requires, when a pharmacy must hand over a Medication Guide, how patient package inserts differ, and where FDA's one-page replacement proposal stands.